Exploring Cardiovascular Autonomic Function before and after Chronic Deep Brain Stimulation in Parkinson's Disease

Mov Disord Clin Pract. 2024 Jun;11(6):698-703. doi: 10.1002/mdc3.14060. Epub 2024 May 2.

Abstract

Background: Blood pressure control in Parkinson's disease (PD) under subthalamic deep brain stimulation (STN-DBS) is influenced by several intertwined aspects, including autonomic failure and levodopa treatment.

Objective: To evaluate the effect of chronic STN-DBS, levodopa, and their combination on cardiovascular autonomic functions in PD.

Methods: We performed cardiovascular reflex tests (CRTs) before and 6-months after STN-DBS surgery in 20 PD patients (pre-DBS vs. post-DBS). CRTs were executed without and with medication (med-OFF vs. med-ON).

Results: CRT results and occurrence of neurogenic orthostatic hypotension (OH) did not differ between pre- and post-DBS studies in med-OFF condition. After levodopa intake, the BP decrease during HUTT was significantly greater compared to med-OFF, both at pre-DBS and post-DBS evaluation. Levodopa-induced OH was documented in 25% and 5% of patients in pre-DBS/med-ON and post-DBS/med-ON study.

Conclusion: Chronic stimulation did not influence cardiovascular responses, while levodopa exerts a relevant hypotensive effect. The proportion of patients presenting levodopa-induced OH decreases after STN-DBS surgery.

Keywords: advanced Parkinson's disease; autonomic failure; deep brain stimulation; neurostimulation; orthostatic hypotension.

MeSH terms

  • Aged
  • Antiparkinson Agents* / adverse effects
  • Antiparkinson Agents* / therapeutic use
  • Autonomic Nervous System* / drug effects
  • Autonomic Nervous System* / physiopathology
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Deep Brain Stimulation* / methods
  • Female
  • Humans
  • Hypotension, Orthostatic / etiology
  • Hypotension, Orthostatic / physiopathology
  • Hypotension, Orthostatic / therapy
  • Levodopa* / administration & dosage
  • Levodopa* / adverse effects
  • Levodopa* / therapeutic use
  • Male
  • Middle Aged
  • Parkinson Disease* / physiopathology
  • Parkinson Disease* / therapy
  • Subthalamic Nucleus / physiopathology

Substances

  • Levodopa
  • Antiparkinson Agents